Eli Lilly has finalized a $2.4 billion acquisition of Orna Therapeutics, advancing its capabilities in genetic therapies and in vivo cell engineering for autoimmune diseases. The move comes as Lilly leverages its strong revenue growth outlook of up to $83 billion for 2026, fueled by its successful diabetes and obesity drug portfolio, despite facing stiff competition from Novo Nordisk. This deal, along with collaborations in oncology and immunology, reinforces Lilly's strategy to lead in innovative therapeutic solutions.
“Though other companies, from Pfizer to Viking Therapeutics, aim to enter the market in the coming years, Lilly's lead and brand strength should keep revenue climbing well into the future.”
“Novo's stock faced pressure recently after rival Eli Lilly's shares rallied last week following the release of its fourth quarter earnings, and it now expects 2026 revenue to grow, compared to Novo, which said it expected sales to fall this year.”
“Eli Lilly is paying $350 million upfront to collaborate with Chinese biotech Innovent in developing new treatments for cancer and immune disorders, a further vote of confidence for the innovation capabilities of the country’s drugmakers.”
“Eli Lilly to buy Orna Therapeutics, which focuses on ‘in vivo’ CAR-T for autoimmune diseases, for $2.4 billion”
“Eli Lilly will pay up to $2.4 billion to acquire Orna Therapeutics, a biotechnology firm that is developing a technology to turn a patient’s own cells into cell therapies without removing them from the body.”
“Eli Lilly & Co agreed to buy US biotech Orna Therapeutics for up $2.4 billion in cash in the latest deal by the company best known for its weight-loss drug Zepbound.”
“It's no secret that Eli Lilly's (NYSE: LLY) strong performance in recent years is due in large part to its clinical and commercial progress with tirzepatide, a medicine approved for diabetes and weight loss. This therapy's sales are growing rapidly, helping the pharmaceutical leader post excellent financial results.”
“Eli Lilly is looking to further boost its clinical trial success rate. That's why the drugmaker is investing in artificial intelligence (AI), notably by building what will become the industry's largest AI supercomputer, among other initiatives.”
“All this shows that, once again, Eli Lilly is at the forefront of innovation in its industry. On top of that, the company is recording strong financial results, boasts a deep pipeline, and continues to reward shareholders with growing dividends and share buybacks.”
“Eli Lilly (LLY) has agreed to acquire biotechnology company Orna Therapeutics for up to $2.4B in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical development milestones.”
“The deal provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering.”
“And this week, Lilly announced a $2.4 billion acquisition of Orna Therapeutics, which is developing innovative drugs that can manipulate a patient's genes and/or cells to fight diseases -- inside a patient's body, not in a lab.”
